Needham & Company LLC reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report report published on Friday morning,Benzinga reports. Needham & Company LLC currently has a $6.00 price target on the biopharmaceutical company's stock.
ESPR has been the topic of a number of other reports. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th.
Read Our Latest Report on Esperion Therapeutics
Esperion Therapeutics Stock Performance
Shares of NASDAQ:ESPR traded down $0.30 during trading on Friday, hitting $2.25. The company's stock had a trading volume of 33,909,558 shares, compared to its average volume of 6,387,248. The company has a market capitalization of $443.34 million, a PE ratio of -3.52 and a beta of 1.01. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The stock's 50-day moving average price is $2.39 and its two-hundred day moving average price is $2.22.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in ESPR. BOKF NA acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at about $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth approximately $27,000. Xponance Inc. acquired a new position in Esperion Therapeutics during the 2nd quarter valued at approximately $28,000. National Bank of Canada FI grew its stake in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter valued at $44,000. Institutional investors and hedge funds own 47.39% of the company's stock.
About Esperion Therapeutics
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Articles
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
